Early research on Depo-Provera primarily focused on bone density and cardiovascular health. More recent studies have also examined whether prolonged exposure to depot medroxyprogesterone acetate (DMPA) may be associated with an increased risk of certain brain tumors.
Research published by the National Cancer Institute (NCI) and other scientific publications has discussed a possible association between long-term DMPA use and meningioma risk. However, research is ongoing, and every individual’s medical history and circumstances are unique.
A case-control study published in Cancer Research also examined whether certain progestin-based contraceptives may be associated with an increased risk of meningiomas. Meningiomas are typically benign tumors but may cause significant health complications depending on their size and location. Additional research continues to evaluate these potential associations.